INTRODUCTION AND OBJECTIVES:
There is a paucity of effective treatment options for patients with BCG-unresponsive NonMuscle Invasive Bladder Cancer (NMIBC) and alternatives to radical cystectomy are desperately needed. Next-generation sequencing makes it possible to identify and prioritize therapeutic opportunities for clinical trial of novel targeted agents.
METHODS: We identified urothelial bladder cancer patients within our institutional genomic database and in the publicly available The Cancer Genome Atlas (TCGA) dataset who had progressed to muscle invasive disease after at least one course of intravesical BCG. DNA from BCG treated, chemotherapy naive, secondary MIBC tumors and matched normal DNA underwent targeted exome capture sequencing or whole exome sequencing. Potentially actionable genomic alterations were defined according to the Precision Oncology Knowledge Base levels of evidence (OncoKB.org).
RESULTS: The cohort was comprised of 77 secondary MIBC specimens. Sixty-six (86%) were male and the median age was 67 years (IQR[61, 75) . Alterations in the RTK/MAPK pathway were seen in 42% of cohort, with non-overlapping FGFR3 (18%) and ERBB2 (15%) being most commonly altered genes. Activating PIK3CA mutations occurred in 21% of specimens; often co-occurring with RTK/MAPK pathway alterations that may be potential resistance mechanisms to FGFR or ERBB2 directed monotherapies. Loss of CDKN2A in FGFR3 mutated tumor, hypothesized to be a driver of muscle invasive progression, occurred in 10% of samples. Alterations in cell cycle regulators were seen in 65% of specimens, of which 40% also had an intact RB gene and could potentially be vulnerable to CDK4/6 inhibitors. Inactivating mutations in CREBBP or EP300 occurred in 17% of samples and might confer sensitivity to HDAC inhibitors. Truncating KDM6A mutations were seen in 19%. These might be sensitizing to EZH2 inhibitors. Similarly, truncating mutations in the SWI/SNF chromatin-modifying complex, predominately in ARID1A, occurred in 33% and may also be vulnerable to EZH2 inhibitors.
CONCLUSIONS: Patients in whom BCG has failed have few effective alternative options to radical cystectomy. Genomic profiling, however, reveals that majority of tumors have potentially actionable alterations. Targeted therapy for NMIBC patients warrants further investigation as more selective, less toxic systemic inhibitors are developed and further advances are made in intravesical delivery systems.
Source of Funding: This work was supported by the Sidney Kimmel Center for Prostate and Urologic Cancers, the Michael and Zena Wiener for Therapeutics Program in Bladder Cancer, Pin Down Bladder Cancer, Cycle for Survival, the Marie-Josee and Henry R. Kravis Center for Molecular Oncology, NIH/ NCATS Grant Number UL1-TR002384, and the National Cancer Institute Cancer Center Core Grant Number P30-CA008748.
MP43-06 FLEXIBLE BLUE LIGHT CYSTOSCOPY WITH HEXAMINOLEVULINATE PROVIDES OPPORTUNITY TO FINALIZE DIAGNOSIS AND TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER IN THE OUTPATIENT CLINIC. RESULTS FROM A NORDIC REGISTRY
Gorm von Gohren Edwin*, Baerum, Norway; Anders Debes, Oslo, Norway; Per-Uno Malmstrom, Uppsala, Sweden INTRODUCTION AND OBJECTIVES: Bladder cancer is one of the most prevalent cancer in the world. Approximately 75% of bladder cancers are non-muscle invasive (NMIBC) and requires multiple follow up cystoscopies. Due to its high recurrence rate patients also undergo a high number of transurethral resections (TURBTs). Several studies have shown that blue light cystoscopy (BLC) with hexaminolevulinate improves detection rate of Ta, T1 cancers and carcinoma in situ (CIS). In combination with flexible cystoscopes, both diagnosis and treatment in the outpatient clinic (without the need of anaesthesia) is possible, saving costs and hospital admissions. A Nordic registry study is initiated to observe the clinical value and explore possible benefits of flexible BLC in the outpatient setting.
METHODS: The Nordic Blue Light Flexible Cystoscopy registry (BLFC) is an observational study including patients undergoing blue light cystoscopy with hexaminolevulinate (HexvixÒ/CysviewÒ, Photocure ASA) in the outpatient clinic for suspicion of, or in routine follow-up for NMIBC. Data recorded are patient demographics, bladder cancer history, findings under WLC and BLC, treatment performed, patient preference, physician experience and further management.
RESULTS: To date, the registry includes 208 patients from five hospitals with a total of 370 outpatient visits. Amongst patients with at least one suspicious lesion a total of 344 lesions were identified, of which 223 (65%) were biopsied and 56 lesions were treated (fulgurated) within the same procedure, preventing referral for a transurethral resection (TURBT). 99 lesions (29%) were identifiable only by BLC. 64 (65%) of these lesions were biopsied and for lesions with confirmed malignancy, 30% were CIS and 4% T1. BLC provided added value in 75% of the patients, with a stronger confidence in confirming/refuting a suspicious lesion as the main advantage (27%). 95% of the patients preferred the outpatient procedure over a TURBT in the OR.
CONCLUSIONS: Flexible BLC as an adjunct to WLC in the outpatient clinic improves detection rate of malignant lesions and provides the possibility to finalize the diagnosis and treatment of the patients in the outpatient clinic, reducing the need for TURBT. Patients tolerate the treatment well and prefer this procedure over TURBT in the OR.
Source of Funding: Photocure ASA contributes financially to the registry study.
MP43-07
A URINE ASSAY TO TRIAGE PATIENTS WITH HEMATURIA FOR CYSTOSCOPY INTRODUCTION AND OBJECTIVES: The prevalence of hematuria in the general population is estimated to be 9-18%. Cystoscopy is recommended to rule out the presence of a bladder tumor. Given the low incidence of bladder cancer and the invasive nature of cystoscopy, a urine test to rule out patients for cystoscopy is an unmet need. Here, we validate a sensitive urine assay in a large prospective cohort of patients presenting with hematuria. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e619
Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
